MVR-EX101

MVR-EX101 is an investigational drug candidate currently in the discovery phase. It is being developed as a HER2 antagonist, which means it targets and inhibits the activity of the human epidermal growth factor receptor 2 (HER2). HER2 antagonists are typically explored for their potential in treating diseases where HER2 plays a role, such as certain cancers or other proliferative disorders. The initial developer of MVR-EX101 is Shenzhen Yinuowei Medical Technology. There are indications that ImmVira may also be involved with this compound or related exosome-based therapies, but primary development attribution remains with Shenzhen Yinuowei Medical Technology[1][6]. The main indication under investigation appears to be diabetic ulcer[3].